>
Fusion Antibodies logo

FAB - Fusion Antibodies Share Price

127.5p 0.0  0.0%

Last Trade - 16/06/21

Sector
Healthcare
Size
Micro Cap
Market Cap £32.9m
Enterprise Value £30.0m
Revenue £4.05m
Position in Universe 1366th / 1812
Bullish
Bearish
Unlock FAB Revenue
Momentum
Relative Strength (%)
1m -13.7%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -50.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.91 1.48 1.91 2.69 2.18 3.90 4.00 4.60 +33.8%
-89.6
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 September 2020, FusionAntibodies PLC revenues increased 9% to £1.9M. Net lossincreased less than 1% to £471K. Revenues reflect anincrease in demand for the Company's products and servicesdue to favorable market conditions., offset byAdministrative expenses increase of 5% to £1.5M (expense),Other operating income decrease of 19% to £43K (income),Bank interest receivable decrease of 75% to £1K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

FAB Revenue Unlock FAB Revenue

Net Income

FAB Net Income Unlock FAB Revenue

Normalised EPS

FAB Normalised EPS Unlock FAB Revenue

PE Ratio Range

FAB PE Ratio Range Unlock FAB Revenue

Dividend Yield Range

FAB Dividend Yield Range Unlock FAB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
FAB EPS Forecasts Unlock FAB Revenue
Profile Summary

Fusion Antibodies PLC, formerly Fusion Antibodies, Ltd., is a United Kingdom-based cancer therapeutics developer. The Company develops and commercializes antibody-based therapeutics for cancer. The Company develops a range of antibody engineering services based around monoclonal antibodies. It focuses in the expression and purification of recombinant proteins and chimeric antibodies for the research, diagnostic and therapeutic markets. Its technology generates target specific antibodies from protein antigens. The Company's therapeutic and diagnostic research and development are offered as a service to pharmaceutical, biopharmaceutical and academic researchers.

Directors
Last Annual March 31st, 2020
Last Interim September 30th, 2020
Incorporated November 29, 2000
Public Since December 18, 2017
No. of Shareholders: n/a
No. of Employees: 47
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 25,818,278
Free Float (0.0%)
Eligible for
ISAs
SIPPs
FAB Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for FAB
Upcoming Events for FAB
Monday 16th August, 2021 Estimate
Full Year 2021 Fusion Antibodies PLC Earnings Release
Friday 24th September, 2021 Estimate
Fusion Antibodies PLC Annual Shareholders Meeting
Frequently Asked Questions for Fusion Antibodies
What is the Fusion Antibodies share price?

As of 16/06/21, shares in Fusion Antibodies are trading at 127.5p, giving the company a market capitalisation of £32.9m. This share price information is delayed by 15 minutes.

How has the Fusion Antibodies share price performed this year?

Shares in Fusion Antibodies are currently trading at 127.5p and the price has moved by 30.77% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Fusion Antibodies price has moved by 10.95% over the past year.

What are the analyst and broker recommendations for Fusion Antibodies?

Of the analysts with advisory recommendations for Fusion Antibodies, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Fusion Antibodies is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Fusion Antibodies next release its financial results?

Fusion Antibodies is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Fusion Antibodies dividend yield?

Fusion Antibodies does not currently pay a dividend.

Does Fusion Antibodies pay a dividend?

Fusion Antibodies does not currently pay a dividend.

When does Fusion Antibodies next pay dividends?

Fusion Antibodies does not currently pay a dividend.

How do I buy Fusion Antibodies shares?

To buy shares in Fusion Antibodies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Fusion Antibodies?

Shares in Fusion Antibodies are currently trading at 127.5p, giving the company a market capitalisation of £32.9m.

Where are Fusion Antibodies shares listed? Where are Fusion Antibodies shares listed?

Here are the trading details for Fusion Antibodies:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: FAB
What kind of share is Fusion Antibodies?

Based on an overall assessment of its quality, value and momentum, Fusion Antibodies is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Fusion Antibodies share price forecast 2021?

We were not able to load any forecast data for Fusion Antibodies.

How can I tell whether the Fusion Antibodies share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fusion Antibodies. Over the past six months, the relative strength of its shares against the market has been -9.46%. At the current price of 127.5p, shares in Fusion Antibodies are trading at -5.72% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Fusion Antibodies PE Ratio?

We were not able to find PE ratio data for Fusion Antibodies.

Who are the key directors of Fusion Antibodies?

Fusion Antibodies's management team is headed by:

John Maynard - DRC
Alan Mawson - DRC
John Ivan George Cadogan - CHM
James Johnston - CSO
Richard Jones - CEO
Who are the major shareholders of Fusion Antibodies?

Here are the top five shareholders of Fusion Antibodies based on the size of their shareholding:

Amati Global Investors Limited Investment Advisor
Percentage owned: 9.07% (2.34m shares)
Crescent Capital NI Limited Venture Capital
Percentage owned: 8.61% (2.22m shares)
Clarendon Fund Managers Limited Venture Capital
Percentage owned: 8.48% (2.19m shares)
Octopus Investments Limited Investment Advisor
Percentage owned: 5.91% (1.53m shares)
Johnston (James) Individual Investor
Percentage owned: 5.1% (1.32m shares)
Similar to FAB
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.